Pfizer Reports P-III Trial (BASIS) Results of Marstacimab for the Treatment of Hemophilia A and B
- The P-III trial evaluated marstacimab in 145 adolescent & adult patients aged 12-<75yrs. with hemophilia A & B with/out inhibitors
- The trial met its 1EPs & showed a reduction in ABR over prophylaxis & on-demand intravenous regimens, also demonstrated superiority with a 92% reduction in bleeds among patients with on-demand factor replacement IV therapy in the lead-in period
- Superiority with marstacimab over prophylaxis with a 35% reduction in ABR & the safety profile was consistent with P-I/II results, was well-tolerated & no deaths were seen with no thromboembolic events or events of consumptive coagulopathy. The results from the inhibitor cohort of the (BASIS) trial are expected in 2024
Ref: BusinessWire | Image: Pfizer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.